Friday, 16 Feb 2018

You are here

Suspending Methotrexate for Influenza Vaccination

Vaccinating our rheumatoid arthritis patients against influenza every year is a safety priorty. However immunosuppressive therapies pose a challenge to vaccine administration as their use can hamper vaccine immunogenicity. The current issue of Annals of Rheumatic Disease published the findings of a prospective single-center randomized parallel group study looking at the effects of temporarily discontinuing methotrexate on response to the seasonal trivalent influenza vaccine in RA patients living in Seoul, Korea.

Patients who were on a stable dose of methotrexate were randomized into one of 4 groups: 1) continued methotrexate, 2) held methotrexate for 4 weeks before vaccination, 3) held methotrexate for 2 weeks before and 2 weeks after vaccination, and 4) held methotrexate for 4 weeks after vaccination. Patients could continue taking prednisolone equivalent up to 10 mg daily. The primary endpoint was satisfactory vaccine response after 4 weeks, defined by a ≥4-fold increase in haemaglutination inhibition (HI) antibody titers. 

The per-protocol population included 199 patients across the four groups. They found that group 3 achieved higher satisfactory vaccine response against all 3 viral antigens compared to group 1 (51.0% vs 31.5%, p=0.044). The vaccine was well tolerated in all patients. 30% experienced an RA flare which was more common in groups 2 and 3 but not of statistical significance. 

While the authors were unable to enroll enough patients to meet their target due to short enrollment period (thus rendering this study underpowered), it still has important clinical implications and suggests that temporarily discontinuing methotrexate 2 weeks before and 2 weeks after influenza vaccination can significantly improve vaccine immunogenicity. It is unclear if the same result can be expected for patients with active RA. Also, further studies are needed to determine if this effect will result in lower incidence of influenza. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

ACIP Guidelines on H. Zoster Vaccination Updated

The ACIP has discussed and analyzed its VZV vaccination policy to ensure safety and reduce disease burden. This report serves as a supplement to the 2008 Prevention of Herpes Zoster Recommendations.

Herpes zoster is a localized, usually painful, cutaneous eruption resulting from reactivation of latent varicella zoster virus (VZV). Herpes zoster is common: approximately one million cases occur each year in the United States.

Higher Fracture Risk with PMR and GCA

Corticosteroid therapy is integral to the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) and a new retrospective cohort study from the UK shows that PMR and GCA have similar, increased risk of fractures.

Problems with Biologic Drug Storage

Is your patient’s refrigerator the problem with the inefficacy of biologic therapies? Studies show most patients don't store their biologics correctly, which may be a source of limited drug efficacy.

Prevention of HBV Infection: How Are We Doing?

In 2016 the WHO set out to eliminate HBV infection as a public health threat by 2030. So far, we are far from this goal as vaccine implementation has been suboptimal in a number of important patient populations, including patients with rheumatologic diseases, as well as other immunocompromising diseases like HIV.

B Cell Changes Predict Autoimmunity with Checkpoint Inhibitors

The Journal of Clinical Investigation reports results of a study showing that increases in CD21lo B cells and plasmablasts following that combination checkpoint blockade preceded the onset of immune-related adverse events.

While some have postulated that IRAEs are thought to be T cell mediated, B cells have also been implicated. Investigators studied 39 melanoma patients undergoing treatment with either anti-CTLA4 or anti-PD1, or combination CCB therapy. They analyzed changes in circulating B cells before and after the first cycle of therapy of immune checkpoint blockade (23 received combination therapy, 8 received anti-CTLA4, and 8 received anti-PD1).